Primer probe composition, kit and method for detecting K562 engineering cell residues
By constructing and optimizing the primer probe composition for target fragments and quality-controlled IPCs, combined with multiple fluorescence quantitative PCR technology, the sensitivity and accuracy of K562 engineering cell residue detection was solved, and the K562 engineering cell residue in cell therapy products was achieved. Efficient inspection ensures product quality and safety.
Patent Information
- Application Number
- CN202411536764.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-31
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
During the cellular drug production process, the residue of K562 engineered cells may lead to tumorigenicity and exogenous factor contamination, and the prior art is difficult to detect sensitively and accurately, affecting product quality and safety.
A primer probe composition and kit for detecting residual K562 engineering cells was developed. By specifically constructing upstream and downstream primers and probes of target fragments and quality-controlled IPCs, the reaction system is optimized, and combined with multiple fluorescence quantitative PCR technology, the reaction system is achieved. Accurate detection of K562 engineering cell residues in cell therapy products such as NK, TIL, and γδT.
This method can sensitively and accurately detect K562 engineering cell residues, improve the accuracy and efficiency of detection, reduce non-specific amplification, reduce experimental errors and costs, and ensure the quality and safety of cell therapy products.
Smart Images

Figure CN119020510A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biotechnology, and in particular to a primer-probe composition, a kit and a method for detecting residual K562 engineered cells. Background Art
[0002] K562 cells are transformed into trophoblast cells by introducing membrane-bound interleukin factors, expressing specific ligands, and antigen-specific gene editing, which can achieve directional regulation of K562 cell functions, namely K562 engineered cells. K562 engineered cells are inhibited from proliferating by irradiation. The irradiated K562 engineered cells will not continue to divide, preventing them from overgrowing and contaminating target cells during culture, thereby reducing the risk of injecting them into the body together with target cells. Irradiated K562 engineered cells are widely used in the in vitro expansion and activation of immune cells such as NK, TIL, and γδT, which can improve the expansion efficiency of immune cells on the one hand. K562 engineered cells provide immune cells (such as NK, TIL, and γδT cells) with stronger expansion potential by expressing specific ligands and cytokines, which helps to obtain a large number of immune cells in a short time. At the same time, the irradiated K562 engineered cells cannot continue to proliferate, reducing the risk of contaminating target cells and injecting them into the body, and ensuring the purity and safety of the expansion process. On the other hand, it promotes immune effects. In addition to the expansion effect, K562 engineered cells can also enhance the immune effects of immune cells, improve the killing activity and sustained survival ability of NK, TIL, and γδT cells in the body, thereby enhancing the efficacy of cell therapy.
[0003] In the production process of cell drugs, the risks of exogenous factor contamination, tumorigenicity and tumorigenicity that may be introduced by trophoblast cells are strictly regulated by domestic and foreign drug regulatory agencies. The 2020 edition of the "Chinese Pharmacopoeia" and the 2023 edition of the "United States Pharmacopoeia" list trophoblast cells as the raw materials and auxiliary raw materials with the highest risk level, respectively. Although K562 engineered cells are irradiated and easily killed by growing NK cells, etc., it is still necessary to ensure that there are as few K562 engineered cells as possible in the final cell product to ensure patient safety. Therefore, it is necessary to develop a highly sensitive detection method for residual K562 engineered cells to ensure effective characterization of process research and final products, and reduce the impact of K562 engineered cells on product quality and safety. Therefore, this field urgently needs to develop a detection method for residual K562 engineered cells in cell therapy products such as NK, TIL, and γδT. Summary of the invention
[0004] In order to overcome the above-mentioned defects of the prior art, the present application constructs and optimizes upstream primers, downstream primers, probes and standards for specific construction of target fragments and quality control IPCs, optimizes the reaction system, and develops a method for detecting residual K562 engineered cells in cell therapy products, which can sensitively and accurately detect residual K562 engineered cells in cell therapy products such as NK, TIL, γδT, etc.
[0005] The first aspect of the present application provides a primer-probe composition for detecting residual K562 engineered cells in a cell therapy product, comprising primers and probes for a target fragment, and primers and probes for a quality control IPC; the primers for the target fragment include the nucleotide sequences shown in SEQ ID NO.1~2; the primers for the quality control IPC include the nucleotide sequences shown in SEQ ID NO.4~5; the probes for the target fragment include the nucleotide sequences shown in SEQ ID NO.3; and the probes for the quality control IPC include the nucleotide sequences shown in SEQ ID NO.6.
[0006] The second aspect of the present application provides a kit for detecting residual K562 engineered cells in a cell therapy product, comprising the primer-probe combination of the first aspect.
[0007] The third aspect of the present application provides a method for detecting residual K562 engineered cells in a cell therapy product, comprising using the primer-probe combination of the first aspect or the kit of the second aspect to amplify the nucleic acid in the sample to be tested, and calculating the residual K562 engineered cells based on the detection results after amplification.
[0008] The residual K562 engineering cells were calculated according to the following formula: residual K562 engineering cells = detection results of primer and probe amplification of target fragment / detection results of primer and probe amplification of quality control IPC × 100%.
[0009] The fourth aspect of the present application provides the use of the primer-probe composition of the first aspect, or the kit of the second aspect, or the method of the third aspect in the quality control and detection of cell therapy products, or in the preparation of cell therapy products.
[0010] The beneficial effects of this application are:
[0011] This application establishes a method for detecting residual K562 engineered cells by specifically constructing and optimizing upstream primers, downstream primers, probes and standards of target fragments and quality control IPCs, which can sensitively and accurately detect residual K562 engineered cells in cell therapy products such as NK, TIL, and γδT. This application can reduce nonspecific amplification and further improve the accuracy of detection through optimized reaction system and primer design. The amplification efficiency of residual K562 engineered cells detection is 85~110%, and the detection results are stable and reliable.
[0012] This application selects different fluorescent markers to avoid fluorescence interference between different target genes, reduce background signals, and improve the specificity and accuracy of detection.
[0013] In the present application, each primer and probe are combined in the same system, and detecting all targets in the same reaction can reduce inter-experimental variation and improve data consistency and comparability; it also reduces the experimental operation steps. Since multiple target genes are detected in one reaction, the sample packaging, reagent addition and other operation steps are reduced, the risk of operational errors is reduced, and the use of experimental consumables is also reduced, saving costs; in addition, since all targets are amplified in the same reaction tube, the risk of cross-contamination between different samples is reduced.
[0014] The method of this application has completed methodological validation, has strong specificity, high accuracy, and good repeatability. It can be used for quality research, release testing, stability research, comparability research, etc. of cell therapy products, and has broad market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Prepare the reaction solution for reverse transcription in Example 1.
[0016] Figure 2 This is the reaction procedure for reverse transcription in Example 1.
[0017] Figure 3 is the dilution of the standard in Example 1.
[0018] Figure 4 This is the preparation of the PCR mixed solution in Example 1.
[0019] Figure 5 The figure shows the sample loading conditions of each reaction well in the PCR in Example 1.
[0020] Figure 6 This is the PCR reaction procedure for amplifying sample nucleic acid in Example 1.
[0021] Figure 7 This is the test result of the sample detection limit in Example 2.
[0022] Figure 8 This is the test result of the specificity of the detection method in Example 3.
[0023] Fig. 9 This is the test result of the accuracy of the detection method in Example 4.
[0024] Fig.10 This is the test result of the repeatability of the detection method in Example 5.
[0025] Fig.11 This is the test result of the precision of the detection method in Example 6.
[0026] Fig.12 The linear range and quantitative limit detection results of the K562 target fragment in Example 7.
[0027] Fig.13 The linear range and quantitative limit detection results of the quality control IPC in Example 7.
[0028] Fig.14 This is the test result of dilution reliability of the detection method in Example 8. DETAILED DESCRIPTION
[0029] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0030] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0031] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0032] This application specifically constructs and optimizes the upstream primers, downstream primers, probes and standards of the target fragment and quality control IPC, optimizes the reaction system, and develops a method for detecting the residual K562 engineered cells in cell therapy products. It can sensitively and accurately detect the residual K562 engineered cells in NK, TIL, γδT and other cell therapy products, with strong specificity, high accuracy and good repeatability.
[0033] Therefore, the present application first provides a primer-probe composition for detecting residual K562 engineered cells in cell therapy products, including primers and probes for target fragments, and primers and probes for quality control IPCs; the primers for the target fragments include the nucleotide sequences shown in SEQ ID NO.1~2; the primers for the quality control IPCs include the nucleotide sequences shown in SEQ ID NO.4~5; the probes for the target fragments include the nucleotide sequences shown in SEQ ID NO.3; and the probes for the quality control IPCs include the nucleotide sequences shown in SEQ ID NO.6.
[0034] In the present application, the cell therapy product refers to the bioengineering of autologous or allogeneic somatic cells or stem cells to form cell products with functions such as killing pathogens and tumor cells, promoting tissue and organ regeneration and body recovery, and then transplanted or introduced into the human body to achieve the purpose of treating diseases. It may include genetically modified or non-genetically modified cells, such as autologous or allogeneic immune cells, stem cells, tissue cells or cell lines, such as NK, TIL, γδT and other cells.
[0035] In this application, the K562 engineered cell residues refer to the residues of K562 engineered cells or their derivatives that may exist in the preparation process of cell therapy products. K562 engineered cells are a human chronic myeloid leukemia cell line, which is often used as a source of feeder cells in cell therapy products, especially in the in vitro expansion of NK cells, TIL cells, etc. Since K562 engineered cells themselves are a source of tumor cells, their residues in cell therapy products may cause potential tumorigenic risks and exogenous factor contamination.
[0036] The primers for the target fragment include an upstream primer and a downstream primer.
[0037] Upstream primer of target fragment: CCTCCACTGAGCCAGTGAAT (SEQ ID NO. 1).
[0038] Downstream primer of target fragment: GAACCTACTGCCCGCAGAA (SEQ ID NO. 2).
[0039] Probe for target fragment: CACAGATCAGGAGCC (SEQ ID NO. 3).
[0040] Primers for quality control IPC include upstream primers and downstream primers.
[0041] Upstream primer for quality control IPC: TGTTAAGCCACACCATGAA (SEQ ID NO. 4).
[0042] Downstream primer for quality control IPC: ACGCACCACCATGGTAGCA (SEQ ID NO. 5).
[0043] Quality control IPC probe: CATGGCTGAGTCCGAAGCATCTACATC (SEQ ID NO. 6).
[0044] In a specific embodiment of the present application, in the primer-probe composition, the final concentration of each component is as follows: 0.2~0.4 μM of the upstream primer of the target fragment, 0.2~0.4 μM of the downstream primer of the target fragment, 0.1~0.3 μM of the probe of the target fragment, 0.2~0.4 μM of the upstream primer of the quality control IPC, 0.2~0.4 μM of the downstream primer of the quality control IPC, and 0.1~0.3 μM of the probe of the quality control IPC.
[0045] In the present application, the quality control IPC refers to an internal reference gene, which is a gene that is relatively constantly expressed in cells. The primers and probes of the quality control IPC are used to amplify the internal reference gene.
[0046] In a specific embodiment of the present application, the above-mentioned primers and probes can exist in the same system, and the target fragments and quality control IPCs can be amplified in the same system. Detecting all targets in the same reaction system can reduce inter-experimental variation, improve data consistency and comparability, and reduce the risk of cross-contamination between different samples.
[0047] The final concentration refers to the concentration of a component in the final reaction system or solution.
[0048] In a specific embodiment of the present application, the probe contains a fluorescent group and a quencher group. Fluorescent groups are a class of chemical substances that can absorb light energy and emit fluorescence. After being excited by light of a specific wavelength, they will emit light of a longer wavelength (fluorescence). Quenching groups are a class of molecules that can absorb and quickly re-emit light energy, or dissipate energy in a non-radiative manner, thereby reducing or eliminating fluorescence. Chemical substances are usually used in combination with fluorescent groups to reduce background fluorescence signals and improve the specificity and sensitivity of detection. When the probe is intact, the fluorescence emitted by the fluorescent group is absorbed by the quencher group, so no detectable fluorescence signal is generated. When the DNA polymerase cuts the probe during the PCR process, the fluorescent group and the quencher group separate, and the fluorescence signal increases accordingly, thereby achieving quantitative detection of the target DNA sequence.
[0049] The fluorescent group can be selected from FAM, SYBR Green, VIC, TET, Cy3, Cy5, Texas Red, AlexaFluor series, BODIPY series. In a specific embodiment of the present application, the fluorescent group is FAM or VIC.
[0050] The quenching group can be selected from MGB, BHQ1, BHQ2, BHQ3, TAMRA. In a specific embodiment of the present application, the quenching group is MGB or BHQ1.
[0051] In a specific embodiment of the present application, the fluorescent group is connected to the 5' end of the probe, and the quenching group is connected to the 3' end of the probe.
[0052] In a specific embodiment of the present application, the 5' end of the probe of the target fragment is FAM, and the 3' end is MGB.
[0053] In a specific embodiment of the present application, the 5' end of the quality control IPC probe is VIC, and the 3' end is BHQ1.
[0054] In a specific embodiment of the present application, the amplification adopts multiplex fluorescence quantitative PCR technology.
[0055] In a specific embodiment of the present application, by selecting different fluorescent markers, fluorescence interference between different target genes is avoided, the background signal is reduced, and the specificity and accuracy of the detection are improved.
[0056] The present application also provides a kit for detecting residual K562 engineered cells in cell therapy products, comprising the above-mentioned primer-probe combination.
[0057] In a specific embodiment of the present application, in the kit, the final concentration of each component is as follows: 0.2~0.4 μM of the upstream primer of the target fragment, 0.2~0.4 μM of the downstream primer of the target fragment, 0.1~0.3 μM of the probe of the target fragment, 0.2~0.4 μM of the upstream primer of the quality control IPC, 0.2~0.4 μM of the downstream primer of the quality control IPC, and 0.1~0.3 μM of the probe of the quality control IPC. Each component can be mixed in a set of amplification system.
[0058] In a specific embodiment of the present application, in the kit, the primers and probes can exist in the same system, and the target fragments and the internal reference genes can be amplified in the same system. Detecting all targets in the same reaction system can reduce inter-experimental variation, improve data consistency and comparability, and reduce the risk of cross-contamination between different samples.
[0059] In a specific embodiment of the present application, the kit further includes reagents required for RNA extraction, such as RNA extraction solution, PBS, enzyme-free deionized water (RNase-Free Water), adsorption columns (Spin Columns RM), buffer, DNaseI enzyme, and anhydrous ethanol.
[0060] In a specific embodiment of the present application, the RNA extraction solution includes TRIzon Reagent and TRIzon PaI™.
[0061] In a specific embodiment of the present application, the buffer includes a reaction buffer (Reaction Buffer), an RW1 washing buffer (Buffer RW1), and an RW2 washing buffer (Buffer RW2).
[0062] In a specific embodiment of the present application, the kit further includes reagents required for RNA reverse transcription, such as RNA template, enzyme-free deionized water (RNase-Free Water), and reverse transcription reaction premix.
[0063] In a specific embodiment of the present application, the reverse transcription reaction premix includes a buffer, a DNA polymerase and dNTPs, and may be, for example, a HiFiScript All-in-one qRT Master Mix product.
[0064] In a specific embodiment of the present application, the kit also includes reagents required for PCR amplification, such as enzyme-free deionized water and PCR reaction premix.
[0065] In a specific embodiment of the present application, the PCR reaction premix includes a buffer, a DNA polymerase, dNTPs, Mg 2+ , for example, it can be the Superfast Probe Mixture product.
[0066] In a specific embodiment of the present application, the kit further comprises a quantitative standard, the concentration of the quantitative standard is 1E+06~10 copies / μL, the concentration can be 1E+06 copies / μL, 1E+05 copies / μL, 1E+04 copies / μL, 1E+03 copies / μL, 1E+02 copies / μL and 10 copies / μL, the quantitative standard is a DNA quantitative standard, which is used to establish a standard curve through a series of quantitative standards of known concentrations, so that the DNA concentration in an unknown sample can be accurately calculated. The quantitative standard contains a target fragment and an internal reference gene of the above concentration, and the target fragment is an E14a2 mutation site fragment in the BCR gene-ABL fusion gene, which refers to the fusion of exon 14 of BCR and exon 2 of the ABL1 gene, and its sequence can be obtained through a gene database.
[0067] The nucleotide sequence of the internal reference gene is shown in SEQ ID NO.7, SEQ ID NO.7: GTGAAAAGCTCCCGGTCTTAGGCTATAATCACAATGGGGAAAGGTGTGAAGCCCAAACCAAAAATGGCCAAGGCTGGGTCCCAAGCAACTACATCACGCCATTCAACAGTCTGGAGAAACACTCCTGGTACCATGGGCCTGTGTC CCGCAATGCCGCTGAGTATCTGCTGAGCAGCGGCATCAATGGCAGCTTCTTGGTGCGTGTGAGTGAGAGCAGTCCTGGCCTGAGGTCCATCTCGCTGAGACGCGAAGGGAGGGTGTACCATTACAGGATCAACACTGCTTCTGATGGCAAG
[0068] The present application also provides a method for detecting residual K562 engineered cells in a cell therapy product, comprising using the above-mentioned primer-probe combination or the above-mentioned kit to amplify the nucleic acid in the sample to be tested, and calculating the residual K562 engineered cells based on the detection results after amplification.
[0069] In a specific embodiment of the present application, the amplification adopts real-time quantitative polymerase chain reaction, i.e., qPCR, and the accumulation of PCR products is monitored by detecting the increase of fluorescent signals.
[0070] In a specific embodiment of the present application, the residual K562 engineered cells are calculated according to the following formula: residual K562 engineered cells = detection result of primer and probe amplification of target fragment / detection result of primer and probe amplification of quality control IPC × 100%.
[0071] In a specific embodiment of the present application, the detection result is the CT value after PCR converted into copy number (copies / μL) through a standard curve.
[0072] In a specific embodiment of the present application, the PCR program for amplifying the nucleic acid in the sample to be tested includes: pre-denaturation: 95~98°C, 3~5min; denaturation: 95~98°C, 15~30s, 40~50 cycles; annealing and extension: 60~65°C, 60~65s, 40~50 cycles.
[0073] In a specific embodiment of the present application, the final concentration of each component in the amplification reaction system is: 0.2~0.4 μM of the upstream primer of the target fragment, 0.2~0.4 μM of the downstream primer of the target fragment, 0.1~0.3 μM of the probe of the target fragment, 0.2~0.4 μM of the upstream primer of the quality control IPC, 0.2~0.4 μM of the downstream primer of the quality control IPC, and 0.1~0.3 μM of the probe of the quality control IPC. For example, in one embodiment of the present application, the amplification reaction system is: 0.3~0.5 μL of the upstream primer (10 μM) of the target fragment, 0.3~0.5 μL of the downstream primer (10 μM) of the target fragment, 0.1~0.3 μL of the probe (10 μM) of the target fragment, 0.3~0.5 μL of the upstream primer (10 μM) of the quality control IPC, 0.3~0.5 μL of the downstream primer (10 μM) of the quality control IPC, 0.1~0.3 μL of the probe (10 μM) of the quality control IPC, 10 μL of the PCR reaction premix (Superfast Probe Mixture), supplemented to 15 μL with enzyme-free deionized water (RNase-Free Water).
[0074] In a specific embodiment of the present application, the method further comprises, before amplifying the nucleic acid in the sample to be tested, extracting RNA from the cell sample and reverse transcribing the RNA.
[0075] In a specific embodiment of the present application, the extraction of RNA from the cell sample can use Ultrapure RNAKit (DNase I), including the following steps: 1) collecting cells; 2) mixing cells with RNA extraction solution; 3) obtaining RNA; 4) purifying RNA.
[0076] In a specific embodiment of the present application, the cells are collected by centrifugation, the centrifugal speed can be 400~600g, the centrifugal time can be 4~6 minutes, the centrifugal speed can be, for example, 400g, 450g, 500g, 550g, 600g, and the centrifugal time can be, for example, 4min, 4.5min, 5min, 5.5min, 6min.
[0077] In a specific embodiment of the present application, the RNA extraction solution includes TRIzon Reagent and TRIzon PaI™, and the ratio of cells: TRIzon Reagent: TRIzon PaI™ can be 1E+6~5E+6 cell: 1mL: 200 μL, for example, it can be 1E6 cell: 1mL: 200 μL, 2E6 cell: 1mL: 200 μL, 3E6 cell: 1mL: 200 μL, 4E6 cell: 1mL: 200 μL, 5E6 cell: 1mL: 200 μL.
[0078] In a specific embodiment of the present application, the RNA is obtained by centrifugation and the upper aqueous phase after centrifugation is taken. The centrifugation temperature can be 4-6°C, the centrifugation speed can be 12000-14000g, the centrifugation time can be 10-15 minutes, the centrifugation temperature can be, for example, 4°C, 5°C, 6°C, the centrifugation speed can be, for example, 12000g, 12500g, 13000g, 13500g, 14000g, and the centrifugation time can be, for example, 10min, 11min, 12min, 13min, 14min, 15min.
[0079] In a specific embodiment of the present application, the purification includes adding ethanol and using an adsorption column for purification. The specific steps may be, for example, adding 600 μL of 70% ethanol to the obtained RNA aqueous phase solution, inverting and mixing 20 times, adding the obtained solution to the adsorption column (Spin Columns RM) loaded in the collection tube, transferring 600 μL of solution at a time, and transferring twice. Centrifuge at 10000g for 1 minute, pour out the waste liquid in the collection tube, and put the adsorption column back into the collection tube. Add 350 μL of Buffer RW1 to the adsorption column, centrifuge at 10000g for 1 minute, pour out the waste liquid in the collection tube, and put the adsorption column back into the collection tube. Add 80 μL of DNase I mixture directly to the adsorption column and incubate at 25°C for 15 minutes. Add 350 μL of Buffer RW1 to the adsorption column, centrifuge at 10000g for 1 minute, discard the waste liquid, and put the adsorption column back into the collection tube. Add 500 μL Buffer RW2 to the adsorption column (check whether anhydrous ethanol has been added before use), centrifuge at 10,000 g for 1 minute, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube. Repeat the previous step, add 500 μL Buffer RW2 to the adsorption column (check whether anhydrous ethanol has been added before use), centrifuge at 10,000 g for 1 minute, discard the waste liquid in the collection tube, and put the adsorption column back into the collection tube. Centrifuge at 12,000 g for 2 minutes and discard the waste liquid in the collection tube. Place the adsorption column at room temperature for 3 minutes and dry it thoroughly. Place the adsorption column in a new 1.5 mL RNase-free centrifuge tube, add 50 μL RNase-Free Water to the middle part of the adsorption column, place it at room temperature for 2 minutes, centrifuge at 12,000 g for 1 minute, collect the RNA solution, and store the RNA at -70°C to prevent degradation.
[0080] In a specific embodiment of the present application, the extracted RNA can also be quantified using an ultraviolet spectrophotometer.
[0081] In a specific embodiment of the present application, the reaction procedure of the reverse transcription includes: 50-55°C, 15-20 minutes; 85-90°C, 5-10 seconds; 4-8°C hold.
[0082] The present application also provides the use of the above-mentioned primer-probe combination, or the above-mentioned kit, or the above-mentioned method in the quality control and detection of cell therapy products, or in the preparation of cell therapy products.
[0083] The quality control and testing of the cell therapy products mentioned above refers to a series of standardized testing and evaluation activities for safety (such as residues of harmful microorganisms, viruses, bacteria or other contaminants), effectiveness, purity, activity, etc. throughout the entire life cycle of the cell therapy products, including raw material testing, cell collection and processing, production process, intermediate product testing, final product inspection and release, including the detection of residual K562 engineered cells.
[0084] The preparation of cell therapy products refers to the extraction, processing, transformation and expansion of cells from specific cell sources to produce cell products for the treatment of diseases. Each step requires precise operation and strict quality control to ensure the safety, efficacy and consistency of the final product, including the detection of residual K562 engineered cells.
[0085] The present application is further described below by way of examples, but the scope of the present application is not limited thereby. Unless otherwise specified, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields conventional in the art. These techniques have been fully described in existing literature.
[0086] Example 1 Detection of residual K562 engineered cells
[0087] 1. Sample extraction
[0088] (1) Take a certain amount of cell suspension (1E6-5E6 cells), centrifuge at 500g for 5 minutes, discard the supernatant, add 1 mL PBS to resuspend, centrifuge at 500g for 5 minutes, discard the supernatant, collect the cells, and add 1 mL TRIzon Reagent.
[0089] (2) After adding TRIzon Reagent to the sample, pipette and mix 20 times continuously to fully lyse the sample. Leave at room temperature for 10 minutes to completely separate the protein-nucleic acid complex.
[0090] (3) Add 200 μL TRIzon PaI™ to every 1 mL TRIzon Reagent, cap the tube, shake vigorously for 30 seconds, and leave at room temperature for 5 minutes.
[0091] (4) Centrifuge at 13400 g for 10 min at 4°C. The sample will then separate into three layers: a red organic phase, an intermediate layer, and an upper colorless aqueous phase. The RNA is mainly in the upper aqueous phase. Transfer 600 μL of the upper aqueous phase to a new 1.5 mL RNase-Free centrifuge tube (be careful not to aspirate the liquid in the intermediate layer).
[0092] (5) Add 600 μL of 70% ethanol to the aqueous solution and mix by inverting 20 times.
[0093] (6) Add all the solution obtained in the previous step to the adsorption column (Spin Columns RM) in the collection tube. Transfer 600 μL of solution at a time, and transfer it twice. Centrifuge at 10,000 g for 1 minute, pour out the waste liquid in the collection tube, and put the adsorption column back into the collection tube.
[0094] (7) Add 350 μL of Buffer RW1 to the adsorption column and centrifuge at 10,000 g for 1 min. Discard the waste liquid in the collection tube and place the adsorption column back into the collection tube.
[0095] (8) Prepare DNase I mixed solution: Take 52 μL RNase-Free Water, add 8 μL 10× Reaction Buffer and 20 μL DNase I (1 U / μL), pipette 10 times to mix, and prepare a final volume of 80 μL reaction solution.
[0096] (9) Add 80 µL of DNase I mixture directly to the adsorption column and incubate at 25°C for 15 min.
[0097] (10) Add 350 μL of Buffer RW1 to the adsorption column, centrifuge at 10,000 g for 1 min, discard the waste liquid, and return the adsorption column to the collection tube.
[0098] (11) Add 500 μL of Buffer RW2 to the adsorption column (check whether anhydrous ethanol has been added before use), centrifuge at 10,000 g for 1 min, pour out the waste liquid in the collection tube, and put the adsorption column back into the collection tube.
[0099] (12) Repeat the previous step and add 500 μL of Buffer RW2 to the adsorption column (check whether anhydrous ethanol has been added before use). Centrifuge at 10,000 g for 1 min, discard the waste liquid in the collection tube, and place the adsorption column back into the collection tube.
[0100] (13) Centrifuge at 12000g for 2 minutes and discard the waste liquid in the collection tube. Place the adsorption column at room temperature for 3 minutes and dry it thoroughly. Note: The purpose of this step is to remove the residual ethanol in the adsorption column. The residual ethanol will affect the subsequent enzymatic reaction (enzyme digestion, PCR, etc.).
[0101] (14) Place the adsorption column in a new 1.5 mL RNase-free centrifuge tube, add 50 μL RNase-Free Water to the middle part of the adsorption column, leave it at room temperature for 2 minutes, centrifuge it at 12,000 g for 1 minute, collect the RNA solution, and store the RNA at -70°C to prevent degradation.
[0102] (15) The extracted RNA was quantified using a UV spectrophotometer and could be directly used in downstream experiments.
[0103] 2. Reverse Transcription
[0104] (1) Genomic DNA removal and reverse transcription reaction.
[0105] After the reagents are melted on the ice box, place them on the ice box according to Figure 1 The reaction solution is prepared using the reaction solution preparation system shown.
[0106] The reaction procedure is as follows Figure 2 shown.
[0107] After the reaction is completed, the obtained cDNA is stored at 4°C or -20°C (long term). Repeated freezing and thawing of cDNA should be avoided. In real-time PCR, it can be added directly or diluted as a template.
[0108] 3. PCR Amplification
[0109] (1) Preparation of standard solution: Take out the quantitative standard (containing 1E+07 copies / μL of target fragments and internal reference genes) and DNA diluent, place in a 4℃ refrigerator to melt; after complete melting, mix by inverting 20 times, centrifuge at 6000 rpm for 5 seconds in a compound rotor centrifuge, and use DNA diluent to dilute the quantitative standard (1E+07 copies / μL) to 1E+06 copies / μL, 1E+05 copies / μL, 1E+04 copies / μL, 1E+03 copies / μL, 1E+02 copies / μL, and 10 copies / μL. The specific operation is as follows: Take 6 1.5 mL centrifuge tubes, mark them as STD1, STD2, STD3, STD4, STD5, STD6, and add 90 μL of DNA diluent to each of the STD1, STD2, STD3, STD4, STD5, STD5, and STD6 tubes. Reference Figure 3 Perform dilution operation. The standard sample is diluted by pipetting and mixing, and pipetting and mixing is performed continuously at a constant speed for 20 times.
[0110] (2) PCR reaction solution preparation
[0111] When preparing the PCR reaction, the order of adding samples is blank control, negative control, test sample and standard. After the negative control and blank control are added, cover the tube cap and seal it for storage. The dilution of the standard and the preparation of the PCR reaction solution need to be completed separately on different clean benches.
[0112] Calculate the number of reaction wells required based on the number of sample tests, and perform 3 replicate tests on each sample. Note: Calculate the total amount of PCR mixture required based on the number of reaction wells: Total amount of PCR mixture = (number of reaction wells + 2) × 15 μL (including the loss of 2 wells). Prepare the PCR mixture in a biosafety cabinet. The preparation of the PCR mixture is as follows: Figure 4 shown.
[0113] K562-F5: Upstream primer of the target fragment, CCTCCACTGAGCCAGTGAAT (SEQ ID NO. 1).
[0114] K562-R5: Upstream primer of the target fragment, GAACCTACTGCCCGCAGAA (SEQ ID NO. 2).
[0115] K562-P5: probe of target fragment, FAM-CACAGATCAGGAGCC-MGB (SEQ ID NO. 3).
[0116] K562-F6: Upstream primer for quality control IPC, TGTTAAGCCACACCATGAA (SEQ ID NO. 4).
[0117] K562-R6: Downstream primer for quality control IPC, ACGCACCACCATGGTAGCA (SEQ ID NO. 5).
[0118] K562-P6: Quality control IPC probe, VIC-CATGGCTGAGTCCGAAGCATCTACATC-BHQ1 (SEQ ID NO.6).
[0119] The loading conditions of each reaction well are as follows Figure 5 shown.
[0120] After adding the sample, put the 8-row lids on, first the two end lids, then the middle lid, and mark the edges of the lids.
[0121] After the sample is added and the tube is sealed, centrifuge it at 6000 rpm for 10 seconds in a compound rotor centrifuge to collect the liquid on the tube wall to the bottom of the tube, then place it on a vortex mixer adjusted to level 6 and shake it for more than 10 seconds to completely mix the reaction solution, then centrifuge it at 6000 rpm for 10 seconds in a compound rotor centrifuge to collect the liquid on the tube wall to the bottom of the tube. If there are bubbles, remove them.
[0122] (3) PCR program settings
[0123] Turn on the PCR instrument and set the PCR reaction program, such as Figure 6 shown.
[0124] Set up the sample reaction plate: edit the information of the standard, NTC, Neg, ERC, and the sample to be tested according to the position of the PCR reaction solution. In the reaction plate chart, select the sample well, select Unknow in the pull-down of Sample Type, check the fluorescent FAM, name the Target Name as K562, check the fluorescent VIC, name the quality control IPC as the Target Name, and enter the number of repetitions and Sample Name for each sample. Enter the number of repetitions and Sample Name for each dilution gradient. And assign values of 1E+06, 1E+05, 1E+04, 1E+03, 1E+02, 10 in the Concentration column of STD1, STD2, STD3, STD4, STD5, and STD6 respectively, and select the unit (copies / μL).
[0125] Open the heating cover, place the eight-tube strip according to the sample plate editing information, close the heating cover, start the PCR run program, and start the PCR reaction.
[0126] 4. Data Processing
[0127] (1) After the reaction is completed, the instrument will automatically set the baseline and threshold. Save and export the results.
[0128] (2) Use Excel to calculate the results: Import the test results directly exported by the instrument into the pre-designed test result analysis table, perform the final test result calculation, and attach the calculated Excel table to the test record.
[0129] (3) Calculation formula: K562 engineered cell residual ratio = detection result of primer and probe amplification of target fragment / detection result of primer and probe amplification of quality control IPC*100%.
[0130] (4) Data saving path: The saving path is the original location where the data is generated.
[0131] (5) Determination of system suitability.
[0132] The coefficient of variation of Ct values among three parallel wells was CV%≤5%, except for the wells with Ct values greater than 35.
[0133] The blank NTC should have no Ct value or be 2 Ct values greater than the lowest concentration of the standard curve.
[0134] PCR reaction amplification efficiency: 85.0%~110.0%, R2≥0.990.
[0135] Example 2 Detection Limit of Detection Method
[0136] Confirmation of sample detection limit: K562 engineered cells with different ratios were used to detect the K562 engineered cells residues according to the method of Example 1. The results are as follows: Figure 7 As shown, when the proportion of K562 engineered cells was 0.05%, the detection Ct value was 32.29 (Ct value < 35), which was the sample detection limit of this detection method.
[0137] Example 3 Specificity of the detection method
[0138] According to the detection method of Example 1, the detection results of the blank control (enzyme-free water) and the negative control (DNA dilution solution) were 0%, and the detection result of the positive control (K562 engineered cells) was 99.27%. Figure 8 .
[0139] Example 4 Accuracy of the detection method
[0140] According to the detection method of Example 1, 2E+06 cells were taken for RNA extraction and reverse transcription. 20 μL of the cDNA sample after reverse transcription was added to 20 μL of STD1 standard as a high-concentration spiked sample (HERC), and three groups were prepared in parallel; 20 μL of the cDNA sample after reverse transcription was added to 20 μL of STD2 standard as a medium-concentration spiked sample (MERC), and three groups were prepared in parallel; 20 μL of the cDNA sample after reverse transcription was added to 20 μL of STD3 standard as a low-concentration spiked sample (LERC), and three groups were prepared in parallel. The detection recovery rates of high, medium and low concentration spiked samples were all between 50% and 150%. The accuracy test results are shown in Fig. 9 .
[0141] Example 5 Repeatability of the detection method
[0142] According to the method of Example 1, 2E+06 cells were taken for RNA extraction and reverse transcription, and the cDNA after reverse transcription was added to 20 μL STD2 standard, and 6 groups were prepared in parallel. The same concentration was used to prepare 6 groups in parallel. The CV of the 6 parallel tests was less than 20%. The repeatability test results are shown in Fig.10 .
[0143] Example 6 Precision of the Detection Method
[0144] Two analysts took 2E+06 cell samples from the same batch at different times according to the method of Example 1 for RNA extraction and reverse transcription, took the reverse transcribed cDNA and added 20 μL STD2 standard, and prepared 6 groups in parallel. The CV of the test results of 6 parallel samples by the same analyst was less than 20%, and the CV of the test results of 12 parallel samples by two analysts was less than 25%. The intermediate precision test results are shown in Fig.11 .
[0145] Example 7 Linearity, range and limit of quantitation of the detection method
[0146] When the concentration of the quantitative standard is 1E+06 copies / μL~10 copies / μL, the amplification of the K562 target fragment and the quality control IPC meets the linear correlation coefficient R2≥0.99 of the three standard curves, the coefficient of variation of the fitted concentration at each concentration point is ≤25%, and the fitted recovery rate meets 50%~150%. The range of this detection method is between 1E+06 copies / μL~10 copies / μL, and the limit of quantification is 10 copies / μL. The linearity, range and limit of quantification test results are shown in Fig.12 and Fig.13 .
[0147] Example 8 Dilution reliability of the detection method
[0148] According to the method of Example 1, 2E+06 cells were taken for RNA extraction and reverse transcription. 60 μL of cDNA after reverse transcription was added to 60 μL of STD2 standard and mixed well as the dilution reliability verification sample. When the sample was diluted 1 times, 10 times, 50 times and 100 times, the variation dilution of the K562 engineered cell residue detection result was less than 25%. The dilution reliability test results are shown in Fig.14 .
[0149] Example 9 Preparation of a kit for detecting residual K562 engineered cells in cell therapy products
[0150] This embodiment provides a kit for detecting residual K562 engineered cells in a cell therapy product, comprising the following components: a primer-probe combination (primers and probes for target fragments and quality control IPCs), a quantitative standard containing a target fragment of a known specific concentration and an internal reference gene, a template-free control, a negative control, a positive control, an exogenous reference control, an RNA extract (TRIzon Reagent and TRIzon PaI™), a buffer (reaction buffer, washing buffer), a reverse transcription reaction premix, a DNA polymerase, dNTPs, enzyme-free deionized water, a PCR reaction premix, MgCl2, and a 5-well buffer. 2+ , those skilled in the art can configure the above conventional components through conventional techniques or purchase them through commercial channels.
[0151] K562-F5: Upstream primer of the target fragment, CCTCCACTGAGCCAGTGAAT (SEQ ID NO. 1).
[0152] K562-R5: Upstream primer of the target fragment, GAACCTACTGCCCGCAGAA (SEQ ID NO. 2).
[0153] K562-P5: probe of target fragment, FAM-CACAGATCAGGAGCC-MGB (SEQ ID NO. 3).
[0154] K562-F6: Upstream primer for quality control IPC, TGTTAAGCCACACCATGAA (SEQ ID NO. 4).
[0155] K562-R6: Downstream primer for quality control IPC, ACGCACCACCATGGTAGCA (SEQ ID NO. 5).
[0156] K562-P6: Quality control IPC probe, VIC-CATGGCTGAGTCCGAAGCATCTACATC-BHQ1 (SEQ ID NO.6).
[0157] Internal reference gene (SEQ ID NO.7): GTGAAAAGCTCCCGGTCTTAGGCTATAATCACAA TGGGGAAAGGTGTGAAGCCCAAACCAAAAATGGCCAAGGCTGGGTCCCAAGCAACTACATCACGCCATTCAACAGTCTGGAGAAACACTCCTGGTACCATGGGCCTGTGTCCCGCAATGCCGCTGAGTATC TGCTGAGCAGCGGCATCAATGGCAGCTTCTTGGTGCGTGTGAGTGAGAGCAGTCCTGGCCTGAGGTCCATCTCGCTGAGACGCGAAGGGAGGGTGTACCATTACAGGATCAACACTGCTTCTGATGGCAAG
[0158] In the above kit, in the primer-probe composition, the upstream primer of the target fragment is 0.2~0.4 μM, the downstream primer of the target fragment is 0.2~0.4 μM, the probe of the target fragment is 0.1~0.3 μM, the upstream primer of the quality control IPC is 0.2~0.4 μM, the downstream primer of the quality control IPC is 0.2~0.4 μM, the probe of the quality control IPC is 0.1~0.3 μM, and the concentration of the quantitative standard is 1E+06~10 copies / μL.
[0159] The above embodiments are merely illustrative of the principles and effects of the present application and are not intended to limit the present application. Anyone familiar with the technology may modify or change the above embodiments without violating the spirit and scope of the present application. Therefore, all equivalent modifications or changes made by a person of ordinary skill in the art without departing from the spirit and technical ideas disclosed in the present application shall still be covered by the claims of the present application.
Claims
1. A primer-probe composition for detecting residual K562 engineered cells in a cell therapy product, comprising primers and probes for a target fragment, and primers and probes for a quality control IPC; the primers for the target fragment comprise the nucleotide sequences shown in SEQ ID NO.1~2; the primers for the quality control IPC comprise the nucleotide sequences shown in SEQ ID NO.4~5; the probes for the target fragment comprise the nucleotide sequences shown in SEQ ID NO.3; the probes for the quality control IPC comprise the nucleotide sequences shown in SEQ ID NO.
6.
2. The primer-probe combination according to claim 1, characterized in that The probe contains a fluorescent group and a quencher group.
3. The primer-probe composition according to claim 2, characterized in that: The fluorescent group is selected from FAM or VIC; And / or, the quenching group is selected from MGB or BHQ1.
4. A kit for detecting residual K562 engineered cells in a cell therapy product, comprising the primer-probe combination as described in any one of claims 1 to 3.
5. The kit according to claim 4, characterized in that The kit also includes reagents required for RNA extraction, reagents required for RNA reverse transcription, reagents required for PCR amplification and quantitative standards.
6. The kit according to claim 5, characterized in that The concentration of the quantitative standard is 1E+06~10 copies / μL.
7. A method for detecting residual K562 engineered cells in a cell therapy product, comprising using the primer-probe combination described in any one of claims 1 to 3, or the kit described in any one of claims 4 to 6 to amplify the nucleic acid in the sample to be tested, and calculating the residual K562 engineered cells based on the detection results after amplification.
8. The method according to claim 7, characterized in that The residual K562 engineering cells were calculated according to the following formula: residual K562 engineering cells = detection results of primer and probe amplification of target fragment / detection results of primer and probe amplification of quality control IPC × 100%; And / or, the PCR procedure for amplifying the nucleic acid in the sample to be tested includes: preliminary denaturation: 95-98°C, 3-5min; Denaturation: 95~98℃, 15~30s, cycle 40~50 times; annealing and extension: 60~65℃, 60~65s, cycle 40~50 times.
9. The method according to claim 7, characterized in that: The method further comprises, before amplifying the nucleic acid in the sample to be tested, extracting RNA from the cell sample and reverse transcribing the RNA.
10. The method according to claim 9, characterized in that The RNA extraction in the cell sample comprises the following steps: 1) Collect cells; 2) Mixing cells with RNA extraction solution; 3) Obtain RNA; 4) Purify RNA.
11. The method according to claim 10, further comprising any one or more of the following features: 1) The cells are collected by centrifugation, the speed of the centrifugation is 400-600 g, and the time of the centrifugation is 4-6 minutes; 2) The RNA extraction solution includes TRIzon Reagent and TRIzon PaI™, and the ratio of cells: TRIzon Reagent: TRIzon PaI™ is 1E+6~5E+6 cells: 1mL: 200 μL; 3) The RNA is obtained by centrifugation and the upper aqueous phase is taken after centrifugation. The centrifugation temperature is 4-6°C, the centrifugation speed is 12000-14000g, and the centrifugation time is 10-15 minutes; 4) The purification includes adding ethanol and using an adsorption column for purification.
12. Use of the primer-probe combination as described in any one of claims 1 to 3, or the kit as described in any one of claims 4 to 6, or the method as described in any one of claims 7 to 11 in the quality control and detection of cell therapy products, or in the preparation of cell therapy products.
Citation Information
Patent Citations
Proximity-mediated assays for detecting oncogenic fusion proteins
CN102667478A
Primers, probes and kit for detecting leukemia-related fusion genes
CN105296637A
BCR-ABL fusion gene amplification kit and BCR-ABL fusion gene detection kit
CN106399462A
BCR-ABL1 fusion gene e14a2 subtype plasmid candidate reference substance and preparation method and purpose thereof
CN108265117A
Targeting capture probe of tumor fusion gene and application thereof
CN112662771A
